Chapters

Transcript

Video

Since systemic immunotherapy targeting type 2 cytokine signaling will likely be started in younger pediatric populations, for what duration of therapy do you recommend with cytokine-inhibiting biologics such as dupilumab?

Since systemic immunotherapy targeting type 2 cytokine signaling will likely be started in younger pediatric populations, for what duration of therapy do you recommend with cytokine-inhibiting biologics such as dupilumab?


Created by

CMEducation Resources iQ&A Case-By-Case Atopic Dermatitis Medical Intelligence Zone

Presenter

Lawrence Eichenfield, MD

Lawrence Eichenfield, MD

Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital-San Diego
Vice Chair, Department of Dermatology
Professor of Dermatology and Pediatrics
UC San Diego School of Medicine